Welcome to our dedicated page for Kneat Com news (Ticker: KSIOF), a resource for investors and traders seeking the latest updates and insights on Kneat Com stock.
Kneat Com (OTCQX: KSIOF) provides mission-critical digital validation solutions for pharmaceutical, biotechnology, and medical device industries through its Kneat Gx platform. This page aggregates official press releases, regulatory updates, and strategic developments from the company, serving as a centralized hub for tracking its innovation in compliance automation.
Investors and industry professionals will find timely updates on product enhancements, partnership announcements, and operational milestones. Content spans earnings reports, technology certifications, and client success stories relevant to highly regulated sectors. All materials are sourced directly from company communications to ensure accuracy and compliance with financial disclosure standards.
The curated collection enables users to monitor Kneat Com's progress in reducing validation cycle times, expanding global operations, and maintaining ISO/21 CFR compliance. Regular updates provide insights into how the company addresses evolving regulatory requirements across 60+ countries through its SaaS platform.
Bookmark this page for streamlined access to Kneat Com's latest announcements, or check back regularly to stay informed about developments impacting digital validation practices in life sciences and adjacent industries.
Kneat (OTCQC: KSIOF) has secured a significant Master Services Agreement with a major U.S.-based multinational manufacturer of advanced devices and components. The client company, which employs over 30,000 people across 30+ countries, will implement the Kneat Gx platform for two primary purposes:
The platform will be used for Computer Systems Validation across enterprise applications and for Commissioning, Qualification and Validation at 18 manufacturing sites within its medical and healthcare division. This strategic partnership demonstrates Kneat's expanding presence in the life sciences sector beyond pharmaceuticals.
Kneat (OTCQX: KSIOF), a leader in validation and quality process digitization, has achieved top rankings in G2's Fall 2025 Pharma and Biotech Software category reports. The company secured leadership positions in three categories with an impressive G2 Satisfaction Score of 98/100, surpassing the second-ranked company by 20 points.
The company earned leadership recognition in the Grid® Report, Relationship Index, and Mid-Market Grid® Report for Pharma and Biotech. Additionally, Kneat ranked second in the G2 Pharma and Biotech Usability Index, demonstrating strong performance in administration, ease of use, and requirements fulfillment.
Kneat (OTCQX:KSIOF), a leader in digitizing validation and quality processes for life sciences, will present at the Emerging Growth Conference on September 24, 2025, from 9:40 AM to 10:10 AM ET. CEO and co-founder Eddie Ryan will provide a company overview and discuss recent business progress.
The interactive online event will allow shareholders and investors to engage directly with management through a Q&A session. Kneat's flagship platform, Kneat Gx, enables life science companies to digitize validation processes, reduce risk, and accelerate product time-to-market. The company serves many leading global pharmaceutical companies.
Kneat (OTCQC: KSIOF) has secured a three-year Master Services Agreement with a major European equipment manufacturer that operates in multiple industries including healthcare. The unnamed company, which employs over 15,000 people and operates in 120+ countries, will implement Kneat's Gx platform to digitize equipment testing processes.
The deployment will initially begin at two strategic European sites. This marks Kneat's seventh strategic customer win in 2025, following a record-breaking quarter for new customer acquisitions. The partnership aims to enhance delivery quality and client handover processes through digital transformation.
Kneat (OTCQC: KSIOF) has secured a three-year Master Services Agreement with a global medical technology company, a division of a larger Asian manufacturer with over 30,000 employees operating in more than 160 countries. The client will implement the Kneat Gx platform for equipment validation processes.
CEO Eddie Ryan highlighted that this agreement reinforces the industry's confidence in Kneat's solutions within the life sciences sector. The company's growing platform functionality and adoption by major life sciences companies demonstrates Kneat's technical capabilities and strategic value in validation use cases.
Kneat (OTC: KSIOF) reported strong financial results for Q2 2025, with total revenue reaching $15.4 million, up 32% year-over-year. The company's SaaS revenue grew 31% to $14.1 million, while Annual Recurring Revenue (ARR) increased 43% to $64.8 million.
Q2 2025 highlights include improved gross margin of 75%, EBITDA of $3.8 million, and a reduced net loss of $0.4 million compared to a $3.1 million loss in Q2 2024. The company secured multiple significant client wins, including agreements with a multinational generic pharmaceuticals producer and a global healthcare technology company.
Kneat also announced key executive changes, including the appointment of Dave O'Reilly as CFO and the creation of a Chief Innovation Officer role. The company launched Kneat Gx 9.5, enhancing data management capabilities and validation processes.
Kneat (OTC: KSIOF), a company specializing in digitizing and automating validation and quality processes, has scheduled its Q2 2025 financial results release for August 5, 2025 after TSX market close.
The company will host a conference call and Q&A session for analysts on August 6, 2025 at 09:00 ET. CEO Eddie Ryan and CFO Dave O'Reilly, along with outgoing CFO Hugh Kavanagh, will lead the webcast presentation. The financial results will be accessible through the company's investor relations website.
Kneat (OTCQC: KSIOF), a leader in digitizing and automating validation and quality processes, has announced a significant leadership transition. CFO Hugh Kavanagh will retire from the company, with his final day set for August 8th, 2025.
The company has appointed Dave O'Reilly as the new CFO, effective July 7th, 2025. O'Reilly brings substantial experience from his previous role as CFO at Ekco, where he helped scale the company to $200 million in annual revenue. His background includes serving as international controller for a $4 billion-SaaS business, Consensus Cloud Solutions/Ziff Davis Inc.
To ensure continuity, Kavanagh and O'Reilly will work together for a one-month transition period. CEO Eddie Ryan expressed confidence in O'Reilly's ability to contribute to Kneat's continued scaling efforts in the Life Sciences sector.
Kneat (OTCQC: KSIOF) has secured a multi-year Master Services Agreement with a major U.S.-based healthcare technology and diagnostics company. The unnamed company, which employs over 50,000 people and operates manufacturing facilities in more than a dozen countries, will implement Kneat's Gx platform to digitize their Commissioning, Qualification and Validation workflows.
The platform will be deployed at several lead manufacturing sites, focusing on facilities, equipment, and computer systems validation. According to the State of Validation 2025 study, 93% of organizations are now using or planning to use digital validation, up from 86% in 2024.
Kneat (TSX: KSI) (OTC: KSIOF), a company specializing in digitizing and automating validation processes, held its Annual General Meeting (AGM) on May 28, 2025. At the meeting, shareholders voted on two main items: the election of directors and the re-appointment of auditors.
All five nominated directors were successfully elected to the board with strong approval ratings ranging from 96.02% to 100%. Edmund Ryan received unanimous support (100%), while Carol Leaman (99.97%), Nutan Behki (97.32%), Ian Ainsworth (97.27%), and Wade K. Dawe (96.02%) also received overwhelming approval.
Additionally, shareholders approved the re-appointment of KPMG LLP as the company's auditors with 99.91% of votes in favor.
FAQ
What is the current stock price of Kneat Com (KSIOF)?
What is the market cap of Kneat Com (KSIOF)?
